$743.33
-$12.28(-1.62%)
*Data last updated: 2026-04-15 16:09 (UTC+8)
As of 2026-04-15 16:09, Regeneron Pharmaceuticals (REGN) is priced at $743.33, with a total market cap of $78.49B, a P/E ratio of 17.92, and a dividend yield of 0.47%. Today, the stock price fluctuated between $742.74 and $759.99. The current price is 0.07% above the day's low and 2.19% below the day's high, with a trading volume of 637.73K. Over the past 52 weeks, REGN has traded between $737.02 to $775.62, and the current price is -4.16% away from the 52-week high.
REGN Key Stats
Yesterday's Close$746.46
Market Cap$78.49B
Volume637.73K
P/E Ratio17.92
Dividend Yield (TTM)0.47%
Dividend Amount$0.94
Diluted EPS (TTM)43.77
Net Income (FY)$4.50B
Revenue (FY)$14.34B
Earnings Date2026-04-29
EPS Estimate8.95
Revenue Estimate$3.47B
Shares Outstanding105.16M
Beta (1Y)0.397
Ex-Dividend Date2026-02-20
Dividend Payment Date2026-03-05
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
SectorHealthcare
IndustryBiotechnology
CEOLeonard S. Schleifer
HeadquartersTarrytown,NY,US
Official Websitehttps://www.regeneron.com
Employees (FY)15.41K
Average Revenue (1Y)$930.75K
Net Income per Employee$292.33K
Regeneron Pharmaceuticals (REGN) FAQ
What's the stock price of Regeneron Pharmaceuticals (REGN) today?
x
Regeneron Pharmaceuticals (REGN) is currently trading at $743.33, with a 24h change of -1.62%. The 52-week trading range is $737.02–$775.62.
What are the 52-week high and low prices for Regeneron Pharmaceuticals (REGN)?
x
What is the price-to-earnings (P/E) ratio of Regeneron Pharmaceuticals (REGN)? What does it indicate?
x
What is the market cap of Regeneron Pharmaceuticals (REGN)?
x
What is the most recent quarterly earnings per share (EPS) for Regeneron Pharmaceuticals (REGN)?
x
Should you buy or sell Regeneron Pharmaceuticals (REGN) now?
x
What factors can affect the stock price of Regeneron Pharmaceuticals (REGN)?
x
How to buy Regeneron Pharmaceuticals (REGN) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.
